Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Seeks Injunction Against Endotec For Premarket Violations

This article was originally published in The Gray Sheet

Executive Summary

FDA announced Oct. 6 it has brought suit against orthopedic implant manufacturer Endotec seeking to permanently halt sales of the firm's total joint replacement devices

You may also be interested in...



Endotec To Countersue FDA In Response To Injunction Attempt

Endotec President Michael Pappas says his firm will countersue FDA in response to a federal lawsuit seeking a permanent injunction against the company

Endotec To Countersue FDA In Response To Injunction Attempt

Endotec President Michael Pappas says his firm will countersue FDA in response to a federal lawsuit seeking a permanent injunction against the company

Ankle Prosthetic Petition Opposed; Endotec Says AIP Corrective Actions OK’d

A long-pending FDL-1petition under FDA review to reclassify mobile-bearing total ankle replacement prostheses from Class III to Class II faces new opposition

Related Content

UsernamePublicRestriction

Register

MT024059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel